Stock DGX QUEST DIAGNOSTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Quest Diagnostics Incorporated

Equities

DGX

US74834L1008

Healthcare Facilities & Services

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-07 pm EDT 		5-day change 1st Jan Change
142.3 USD -0.21% Intraday chart for Quest Diagnostics Incorporated +0.26% +3.23%
May. 30 JPMorgan Adjusts Price Target on Quest Diagnostics to $155 From $152 MT
May. 29 Transcript : Quest Diagnostics Incorporated Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 09:20 AM

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,384 16,060 21,224 17,817 15,503 15,813 - -
Enterprise Value (EV) 1 17,962 18,917 24,364 21,482 19,683 19,848 19,369 19,084
P/E ratio 17 x 11.4 x 11.1 x 19.6 x 18.4 x 18.2 x 16.7 x 15.1 x
Yield 1.99% 1.88% 1.53% 1.69% - 2.07% 2.09% 2.11%
Capitalization / Revenue 1.86 x 1.7 x 1.97 x 1.8 x 1.68 x 1.67 x 1.62 x 1.57 x
EV / Revenue 2.32 x 2 x 2.26 x 2.17 x 2.13 x 2.1 x 1.98 x 1.89 x
EV / EBITDA 11.6 x 7.66 x 8.49 x 10.4 x 11 x 10.5 x 9.68 x 8.97 x
EV / FCF 21.3 x 11.9 x 13.3 x 16.3 x 22.8 x 21.9 x 17.4 x 13.9 x
FCF Yield 4.69% 8.39% 7.51% 6.12% 4.39% 4.57% 5.75% 7.21%
Price to Book 2.52 x 2.34 x 3.19 x 2.95 x - 2.31 x 2.12 x 1.93 x
Nbr of stocks (in thousands) 134,697 134,766 122,675 113,887 112,435 111,092 - -
Reference price 2 106.8 119.2 173.0 156.4 137.9 142.3 142.3 142.3
Announcement Date 1/30/20 2/4/21 2/3/22 2/2/23 2/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,726 9,437 10,788 9,883 9,252 9,447 9,765 10,102
EBITDA 1 1,549 2,468 2,870 2,059 1,788 1,888 2,002 2,128
EBIT 1 1,220 2,107 2,462 1,742 1,457 1,514 1,615 1,724
Operating Margin 15.79% 22.33% 22.82% 17.63% 15.75% 16.03% 16.54% 17.07%
Earnings before Tax (EBT) 1 1,076 1,884 2,599 1,235 1,130 1,198 1,285 1,399
Net income 1 858 1,431 1,995 946 854 896.9 970.7 1,065
Net margin 11.11% 15.16% 18.49% 9.57% 9.23% 9.49% 9.94% 10.55%
EPS 2 6.280 10.47 15.55 7.970 7.490 7.812 8.518 9.441
Free Cash Flow 1 843 1,587 1,830 1,314 864 906.3 1,113 1,377
FCF margin 10.91% 16.82% 16.96% 13.3% 9.34% 9.59% 11.4% 13.63%
FCF Conversion (EBITDA) 54.42% 64.3% 63.76% 63.82% 48.32% 48% 55.6% 64.69%
FCF Conversion (Net income) 98.25% 110.9% 91.73% 138.9% 101.17% 101.05% 114.68% 129.2%
Dividend per Share 2 2.120 2.240 2.640 2.640 - 2.949 2.978 3.007
Announcement Date 1/30/20 2/4/21 2/3/22 2/2/23 2/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2,744 2,611 2,453 2,486 2,333 2,331 2,338 2,295 2,288 2,366 2,393 2,364 2,329 2,444 2,481
EBITDA 1 659 660 515 504 407 431 473 464 420 436 485.9 483.3 460.5 460.1 507.3
EBIT 1 553 554 435 423 330 350 389 380 338 349 403.9 398.8 362 374.4 435.4
Operating Margin 20.15% 21.22% 17.73% 17.02% 14.14% 15.02% 16.64% 16.56% 14.77% 14.75% 16.87% 16.87% 15.54% 15.32% 17.55%
Earnings before Tax (EBT) 1 502 452 323 351 109 277 317 299 237 266 318 313 286 285 333.5
Net income 1 390 355 234 256 101 202 235 225 192 194 236.2 232.8 205.4 213.5 254.4
Net margin 14.21% 13.6% 9.54% 10.3% 4.33% 8.67% 10.05% 9.8% 8.39% 8.2% 9.87% 9.85% 8.82% 8.74% 10.25%
EPS 2 3.120 2.920 1.960 2.170 0.8700 1.780 2.050 1.960 1.700 1.720 2.069 2.055 1.837 1.896 2.265
Dividend per Share 2 0.6200 0.6600 0.6600 0.6600 0.6600 0.7100 0.7100 - - - 0.7500 0.7500 0.7500 0.7460 0.7641
Announcement Date 2/3/22 4/21/22 7/21/22 10/20/22 2/2/23 4/27/23 7/26/23 10/24/23 2/1/24 4/23/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 3,578 2,857 3,140 3,665 4,180 4,035 3,556 3,271
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.31 x 1.158 x 1.094 x 1.78 x 2.338 x 2.137 x 1.777 x 1.537 x
Free Cash Flow 1 843 1,587 1,830 1,314 864 906 1,113 1,377
ROE (net income / shareholders' equity) 16.5% 24.6% 28.4% 19.1% 14% 15.1% 15.1% 15%
ROA (Net income/ Total Assets) 7.51% 11.4% 13.2% 8.93% 6.36% 6.89% 7.17% 7.52%
Assets 1 11,417 12,590 15,091 10,593 13,430 13,013 13,536 14,160
Book Value Per Share 2 42.40 50.80 54.20 53.10 - 61.70 67.10 73.60
Cash Flow per Share 2 9.140 6.780 17.40 14.60 11.30 11.60 15.20 15.10
Capex 1 400 418 403 404 408 420 426 430
Capex / Sales 5.18% 4.43% 3.74% 4.09% 4.41% 4.45% 4.37% 4.26%
Announcement Date 1/30/20 2/4/21 2/3/22 2/2/23 2/1/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Quest Diagnostics Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
142.3 USD
Average target price
147 USD
Spread / Average Target
+3.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+3.23% 15.81B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+24.66% 88.38B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-21.76% 77.56B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+8.45% 26.97B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+7.94% 18.45B
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-13.50% 16.57B
NATERA, INC. Stock Natera, Inc.
+77.51% 13.65B
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+76.96% 13.06B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+4.72% 12.61B
DAVITA INC. Stock DaVita Inc.
+36.67% 12.56B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. DGX Stock
  4. Financials Quest Diagnostics Incorporated